On the basis of the above amendments and remarks, Applicants believe the application is condition for allowance. Reconsideration of the application and its allowance are requested. If for any reason the Examiner feels that a telephone conference would expedite prosecution of the application, the Examiner is invited to telephone the undersigned at (206) 442-6672.

Respectfully Submitted,

Deborah A. Sawislak

Deborah A. Sawislak
Registration No. 37,438

Enclosures:

Amendment Fee Transmittal (in duplicate)
Facsimile Transmittal Cover Sheet

B

We claim:

1. An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to residues 41 (Gln) to 148 (Ile) as shown in SEQ ID NO: 2, wherein the residue at position 44 is Asp, the residue at position 47 is Asp and the residue at position 135 is Glu, wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO: 115.

2. The isolated polypeptide of claim 1, wherein amino acid residues 71, 78, 122 and 125 are cysteine.

3. The isolated polypeptide of claim 1, wherein the sequence of amino acid residues is at least 95% identical to SEQ ID NO: 2, from residues 41 (Gln) to 148 (Ile).

4. The isolated polypeptide of claim 1, wherein the sequence of amino acid residues is 100% identical to SEQ ID NO: 2 from residues 41 (Gln) to 148 (Ile).

5. The isolated polypeptide of claim 1, wherein the polypeptide stimulates proliferation of NK cells or NK cell progenitors, stimulates activation of NK cells, stimulates proliferation of T cells, stimulates proliferation of B cells stimulated with anti-CD40 antibodies; or reduces proliferation of B cells stimulated with anti-IgM antibodies.

6. An isolated polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO: 2 from residue 32 (Gln) to residue 162 (Ser) or as shown in SEQ ID NO: 56 (Mouse) from residue 23 (Gln) to residue 146 (Ser).

7. The isolated polypeptide of claim 6, wherein the sequence of amino acid residues as shown in SEQ ID NO: 2 is residue 1 (Met) to residue 162 (Ser) or as shown in SEQ ID NO: 56 (Mouse) is residue 1 (Met) to residue 146 (Ser).

8. An isolated polypeptide comprising at least 14 contiguous amino acid residues of SEQ ID NO: 2 or SEQ ID NO: 56, wherein said polypeptide stimulates an antigenic response in a mammal.

9. The isolated polypeptide of claim 8, wherein the amino acid residues are selected from the group consisting of:

(a) amino acid residues 41-56 of SEQ ID NO: 2;

(b) amino acid residues 69-84 of SEQ ID NO: 2;
(c) amino acid residues 92-105 of SEQ ID NO: 2; and
(d) amino acid residues 135-148 of SEQ ID NO: 2.

44. An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to amino acid residue 32 (Gln) to amino acid residue 162 (Ser) as shown in SEQ ID NO: 2, wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO: 115.

45. The isolated polypeptide of claim 44, wherein amino acid residue 44 is Asp, amino acid residue 47 is Asp, and amino acid residue 135 is Glu.

46. An isolated polypeptide comprising a sequence of amino acid residues that is at least 95% identical to amino acid residue 32 (Gln) to amino acid residue 162 (Ser) as shown in SEQ ID NO: 2, wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO: 115.

47. The isolated polypeptide of claim 46, wherein amino acid residue 44 is Asp, amino acid residue 47 is Asp, and amino acid residue 135 is Glu.

48. An isolated polypeptide comprising a sequence of amino acid residues from amino acid residue 41 (Gln) to amino acid residue 145 (Gln) as shown in SEQ ID NO: 2, wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO: 115.

49. An isolated polypeptide comprising a sequence of amino acid residues from amino acid residue 32 (Gln) to amino acid residue 145 (Gln) as shown in SEQ ID NO: 2, wherein the polypeptide binds the zalpha11 receptor as shown in SEQ ID NO: 115.

50. An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to amino acid residue 41 (Gln) to amino acid residue 162 (Ser) as shown in SEQ ID NO: 2, wherein amino acid residue 145 is Asp and amino acid residue 148 is Asp, and wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO: 115.

51. An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to amino acid residue 32 (Gln) to amino acid residue 162 (Ser) as shown in SEQ ID NO: 2, wherein amino acid residue 145 is Asp and

amino acid residue 148 is Asp, and wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO: 115.

52. The isolated polypeptide of claim 51, wherein stimulates proliferation of NK cells or NK cell progenitors, stimulates activation of NK cells, stimulates proliferation of T cells, stimulates proliferation of B cells stimulated with anti-CD40 antibodies; or reduces proliferation of B cells stimulated with anti-IgM antibodies.

53. An isolated polypeptide comprising a sequence of amino acid residue that is at least 90% identical to a sequence as shown in SEQ ID NO: 2, from amino acid residue 41 (Gln) to amino acid residue 145, wherein residue 145 is Asp not Gln, and wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO: 115.

54. The isolated polypeptide of claim 53, wherein the sequence of amino acid residue is identical to SEQ ID NO: 2, except amino acid residue 145 is Asp not Gln, and wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO: 115.

55. An isolated polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO: 56 from residue 23 (Gln) to residue 146 (Ser), wherein the polypeptide binds a zalpha11 receptor as shown in SEQ ID NO: 115.

56. The isolated polypeptide of claim 55, wherein the sequence of amino acid residues as shown in SEQ ID NO: 56 is residue 1 (Met) to residue 146 (Ser).

57. An isolated polypeptide comprising at least 14 contiguous amino acid residues selected from the group consisting of:

(a) amino acid residues 41-56 of SEQ ID NO: 2;

(b) amino acid residues 68-84 of SEQ ID NO: 2;

(c) amino acid residues 92-105 of SEQ ID NO: 2; and

(d) amino acid residues 135-148 of SEQ ID NO: 2, wherein amino acid residue 145 is Asp and amino acid residue 148 is Asp, and wherein said polypeptide stimulates an antigenic response in a mammal.